Stevens S J, Pronk I, Middeldorp J M
Department of Pathology, University Hospital Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
J Clin Microbiol. 2001 Apr;39(4):1211-6. doi: 10.1128/JCM.39.4.1211-1216.2001.
Epstein-Barr virus (EBV) DNA load monitoring in peripheral blood has been shown to be a useful tool for the diagnosis of aberrant EBV infections. In the present study we compared the relative diagnostic values of EBV DNA load monitoring in unfractionated whole blood and simultaneously obtained serum or plasma samples from Burkitt's lymphoma (BL) patients, transplant recipients, human immunodeficiency virus (HIV)-infected individuals, and infectious mononucleosis (IM) patients by a quantitative competitive PCR (Q-PCR). The EBV DNA load in BL patients was mainly situated in the cellular blood compartment (up to 4.5 x 10(6) copies/ml). EBV DNA loads in unfractionated whole blood and parallel serum samples showed no correlation. In transplant recipients, IM patients, and HIV-infected patients, the EBV burden in the circulation was almost exclusively restricted to the cellular blood compartment, because serum or plasma samples from these patients yielded negative results by Q-PCR, despite high viral loads in corresponding whole-blood samples. A 10-fold more sensitive but qualitative BamHI-W-repeat PCR occasionally revealed the presence of EBV at <2,000 copies of EBV DNA per ml of serum. Spiking of 100 copies of EBV DNA in samples with negative Q-PCR results excluded the presence of inhibitory factors in serum or plasma that influenced the Q-PCR result. Serum samples from all populations were often positive for beta-globin DNA, indicating cell damage in vivo or during serum preparation. We conclude that serum is an undesirable clinical specimen for EBV DNA load monitoring because it omits the presence of cell-associated virus and uncontrolled cell lysis may give irreproducible results or overestimation of the DNA load. Unfractionated whole blood is strongly preferred since it combines all blood compartments that may harbor EBV and it best reflects the absolute viral burden in the patient's circulation.
外周血中爱泼斯坦-巴尔病毒(EBV)DNA载量监测已被证明是诊断异常EBV感染的有用工具。在本研究中,我们通过定量竞争PCR(Q-PCR)比较了未分离全血和同时采集的血清或血浆样本中EBV DNA载量监测对伯基特淋巴瘤(BL)患者、移植受者、人类免疫缺陷病毒(HIV)感染者和传染性单核细胞增多症(IM)患者的相对诊断价值。BL患者的EBV DNA载量主要位于细胞血成分中(高达4.5×10⁶拷贝/毫升)。未分离全血和并行血清样本中的EBV DNA载量无相关性。在移植受者、IM患者和HIV感染者中,循环中的EBV负荷几乎完全局限于细胞血成分,因为尽管相应全血样本中的病毒载量很高,但这些患者的血清或血浆样本通过Q-PCR检测结果为阴性。一种灵敏度高10倍但为定性的BamHI-W重复PCR偶尔可在每毫升血清中EBV DNA <2000拷贝时检测到EBV的存在。在Q-PCR结果为阴性的样本中加入100拷贝的EBV DNA排除了血清或血浆中存在影响Q-PCR结果的抑制因子。所有人群的血清样本β-珠蛋白DNA常呈阳性,表明体内或血清制备过程中存在细胞损伤。我们得出结论,血清是EBV DNA载量监测不理想的临床标本,因为它遗漏了与细胞相关的病毒,且不受控制的细胞裂解可能导致结果不可重复或DNA载量高估。强烈推荐使用未分离全血,因为它包含了所有可能携带EBV的血液成分,并且能最好地反映患者循环中的绝对病毒负荷。